Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections
Journal of Antimicrobial Chemotherapy · 05.05.2026 · 81 (6)
DOI: 10.1093/jac/dkag161 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 13.05.2026. Verfasst von Abdullah T Aslan und 53 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Health, Medicine and Behavioural Sciences, UQ Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Negative Bacterial Infections, Cross Infection, Bacteremia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer, University of Queensland.
Abstract (Originalsprache)
Background
Delays in appropriate antimicrobial therapy can increase the risk of all-cause mortality (ACM) in hospital-acquired bloodstream infections (HA-BSIs) caused by Gram-negative bacteria (GNB). We aimed to evaluate the effectiveness of early appropriate antimicrobial therapy (EAAT) compared with late appropriate antimicrobial therapy (LAAT) in this population.
Methods
This study used data from a multi-centre, prospective cohort including adult patients with HA-BSI caused by GNB across 22 Turkish hospitals. A hypothetical target trial allocating participants with HA-BSI caused by monobacterial GNB to either EAAT or LAAT was emulated using the weighting approach. The primary outcome was 14 day ACM; 28 day ACM was a secondary outcome. Cox proportional hazards models with inverse probability weighting were applied to account for confounding, with antibiotic treatment incorporated as a time-dependent variable.
Results
Among 680 patients, 14 day ACM occurred in 14.7% (40/272) of the EAAT group and 42.9% (175/408) of the LAAT group. EAAT was associated with a lower risk of 14 day ACM [adjusted hazard ratio (aHR) = 0.41; 95% CI: 0.28–0.61). Similarly, 26.1% (71/272) of the patients treated with EAAT and 49.5% (202/408) of those receiving LAAT died during 28 day follow-up (aHR = 0.66; 95% CI: 0.50–0.86). In the carbapenem-resistant GNB subset, EAAT reduced the hazard of 14 day ACM (aHR = 0.36; 95% CI: 0.21–0.60) and 28 day ACM (aHR = 0.60; 95% CI: 0.44–0.84). All prespecified and post hoc analyses consistently supported these findings.
Conclusions
EAAT was associated with a survival benefit in individuals with HA-BSI due to GNB. Although these findings support early initiation of appropriate therapy, residual confounding cannot be excluded.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Faculty of Health, Medicine and Behavioural Sciences, UQ Centre for Clinical Research, University of Queensland, Brisbane, QLD, Australia.
- Sunshine Coast University Hospital, Department of General Medicine, Sunshine Coast, QLD, Australia.
- Faculty of Medicine, Department of Medical Microbiology, Inönü University, Malatya, Türkiye.
- Faculty of Medicine, Department of Biostatistics, Hacettepe University, Ankara, Türkiye.
- Department of General Internal Medicine, Infectious Diseases and Tropical Medicine, Antwerp University Hospital, Antwerp, Belgium.
- Ankara Yildirim Beyazit University, Faculty of Medicine, Ankara Bilkent City Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Türkiye.
ORCID-Profile: Abdullah T Aslan, Ayşe Batirel, Adem Köse, Patrick N A Harris, Murat Akova
Förderung
- Pfizer
- University of Queensland
Zitieren
APA
Aslan, A. T., Ezure, Y., Tanriverdi, E. S., Dağ, O., Cimen, C., Kalem, A. K., Kayaaslan, B., Alkan, S., Köylü, B., Ata, E. B., Çağlar, B., Saltoğlu, N., Önal, U., Deniz, S., Ural, O., Öz, M., Bakir, M., Yilmaz, M., Çakmak, R., …, & Study Group for Carbapenem Resistance (SCARE) (2026). Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections. Journal of Antimicrobial Chemotherapy, 81(6). https://doi.org/10.1093/jac/dkag161
Vancouver
Aslan AT, Ezure Y, Tanriverdi ES, Dağ O, Cimen C, Kalem AK, et al. Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections. Journal of Antimicrobial Chemotherapy. 2026;81(6). doi:10.1093/jac/dkag161
BibTeX
@article{Aslan2026,
author = {Aslan, Abdullah T and Ezure, Yukiko and Tanriverdi, Elif Seren and Dağ, Osman and Cimen, Cansu and Kalem, Ayşe Kaya and Kayaaslan, Bircan and Alkan, Sevil and Köylü, Bahadır and Ata, Emine Büşra and Çağlar, Bilge and Saltoğlu, Neşe and Önal, Uğur and Deniz, Seçil and Ural, Onur and Öz, Murtaza and Bakir, Mehmet and Yilmaz, Mesut and Çakmak, Rümeysa and Batirel, Ayşe and Akdoğan, Özlem and Baykam, Nurcan and Erol, Çiğdem and Yanik-Yalçin, Tuğba and Eren-Kutsoylu, Oya Özlem and Türe-Yüce, Zeynep and Kalin-Ünüvar, Gamze and Özer-Şimşek, Zuhal and Güzeldağ, Seda and Köse, Adem and Cihangiroğlu, Mustafa and Yağci-Caglayik, Dilek and Sevinç, Muhammed Burak and Aktaş, Zerrin and Öncül, Oral and Ersöz, Gülden and Kocagöz, Ayşe Sesin and Hazirolan, Gülşen and Ünalan-Altintop, Tuğçe and Dinç, Bedia and Tüzemen, Nazmiye Ülkü and Akçali, Alper and Maçin, Salih and Çalişkan, Ahmet and Hasbek, Mürşit and Ergon, Cem and Ay-Altintop, Yasemin and Şimşek, Müge and Otlu, Barış and Ramsay, Kay A and Harris, Patrick N A and Akova, Murat and Paterson, David L and Study Group for Carbapenem Resistance (SCARE), Study Group for Carbapenem Resistance (SCARE)},
title = {Emulating a target trial of early compared with late initiation of appropriate antibiotic therapy for hospital-acquired monobacterial Gram-negative bloodstream infections},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {6},
doi = {10.1093/jac/dkag161}
}
EUVIMED